NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), an aggressive childhood brain cancer. The program is funded by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address challenges in treating malignant brain tumors by achieving and maintaining therapeutic drug concentrations within the tumor. Convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, but therapeutic benefit can be limited by rapid drug clearance. The Mayo Clinic team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure following localized delivery. The project will begin with large animal studies and may expand to human studies if successful.
The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy while providing real-time physiologic monitoring, offering investigators insight into drug delivery and its effects on the surrounding neural environment.
David Wambeke, Chief Business Officer of NeuroOne, stated, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording."
The CCRF award marks an important milestone in advancing this therapeutic approach toward clinical evaluation and reflects growing interest from academic investigators and biopharmaceutical companies in NeuroOne's drug delivery platform. The company markets minimally invasive electrode technology platforms with FDA-cleared products including Evo® Cortical Electrodes and OneRF® Ablation System. More information is available at nmtc1.com.
